The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia

Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeuti...

Full description

Saved in:
Bibliographic Details
Published inThe Brazilian journal of infectious diseases Vol. 11; no. 1; pp. 174 - 175
Main Authors Rego, Thiago Carlos Gonçalves, Massumoto, Celso Mitsushi, Batista, Rodrigo Siqueira, Moura, Larissa Hanauer de, Soares, Lygia Maria Costa, Gomes, Andréia Patrícia
Format Journal Article
LanguageEnglish
Portuguese
Published Brazil Brazilian Society of Infectious Diseases 01.02.2007
Elsevier
Subjects
Aged
Anti-CD 20 monoclonal
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Cryoglobulinemia - chemically induced
Cryoglobulinemia - drug therapy
Female
hepatitis C
Hepatitis C - drug therapy
Hodgkin's disease
Humans
Immunologic Factors - therapeutic use
INFECTIOUS DISEASES
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Polyethylene Glycols - adverse effects
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Ribavirin - adverse effects
Ribavirin - therapeutic use
Rituximab
Treatment Outcome
type II mixed cryoglobulinemia
Anti-CD 20 monoclonal
type II mixed cryoglobulinemia
hepatitis C
Hodgkin's disease
Online AccessGet full text

Cover

More Information
Summary:Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m(2), per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.
ISSN:1413-8670
1678-4391
DOI:10.1590/S1413-86702007000100038